ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -46.69% | 19.21% | -13.97% | -32.24% | -167.97% |
| Total Depreciation and Amortization | -4.80% | 6.65% | 40.14% | -0.36% | 865.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.70% | 2.13% | -21.12% | 81.94% | 22.58% |
| Change in Net Operating Assets | 215.19% | -597.48% | -1.71% | 89.90% | 2.46% |
| Cash from Operations | -3.36% | 7.57% | -18.83% | 2.82% | -197.00% |
| Capital Expenditure | -- | 100.00% | -286.27% | 43.96% | 69.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.25% | 153.85% | -192.11% | 66.77% | 128.74% |
| Cash from Investing | 15.25% | 153.61% | -192.61% | 67.12% | 128.56% |
| Total Debt Issued | -- | -101.53% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.52% | 271.61% | -82.24% | 272.00% | -52.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -88.51% | -53.52% | -- | -- | -- |
| Cash from Financing | -85.94% | -98.87% | 3,609.49% | 272.00% | -98.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.82% | -327.52% | -31.34% | 206.60% | -198.15% |